The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Delta-radiomics for prediction of pseudoprogression in malignant melanoma treated with immune checkpoint inhibition.
 
Lucas Basler
No Relationships to Disclose
 
Hubert Gabrys
No Relationships to Disclose
 
Sabrina A. Hogan
Travel, Accommodations, Expenses - Merck
 
Marta Bogowicz
No Relationships to Disclose
 
Diem Vuong
No Relationships to Disclose
 
Martin Huellner
Honoraria - GE Healthcare
Research Funding - GE Healthcare
 
Stephanie Tanadini-Lang
Employment - Varian Medical Systems (I)
Stock and Other Ownership Interests - Varian Medical Systems (I)
Research Funding - Siemens Healthineers; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Siemens Healthcare Diagnostics
 
Robert Foerster
No Relationships to Disclose
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Matthias Guckenberger
Consulting or Advisory Role - AstraZeneca; Varian Medical Systems
Research Funding - Varian Medical Systems
Travel, Accommodations, Expenses - AstraZeneca
 
Mitchell P. Levesque
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Novartis; Roche
Patents, Royalties, Other Intellectual Property - EP 14 176 944.8 Levesque, MP, Widmer, D, Raaimakers, M, and Dummer, R. (2014). Means and methods for identifying a patient having a BRAF-positive cancer as a non-responder to a BRAF inhibitor and as a responder to an MAPK/ERK inhibitor. EP16203799.8 Eichh
Travel, Accommodations, Expenses - Bristol-Myers Squibb